단백질 분해효소(프로테아제) K : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2025-2030년)

The Proteinase K Market size is estimated at USD 82.86 million in 2025, and is expected to reach USD 108.40 million by 2030, at a CAGR of 5.52% during the forecast period (2025-2030).

COVID-19 had a significant impact on the growth of the market. Proteinase K had great potential in the detection of COVID-19, which contributed to providing growth avenues to the market. For instance, according to an article published in Frontiers in Cellular and Infection in Microbiology in November 2021, it was observed that proteinase K demonstrated 6% and 88% sensitivity for N and ORF1ab genes, respectively. This showed that the molecular identification of the SARS-CoV2 viral component could be carried out via PK exposure and heat treatment. This has increased its adoption in identifying coronavirus, hence impacting the market growth during the pandemic. Moreover, companies' increasing focus on developing portable and affordable RT-PCR testing kits has increased the demand for proteinase K enzymes for detecting coronavirus infection among the population. For instance, in May 2022, Genes2Me launched the COVFlu Real-Time PCR kit, which detects Influenza A/B, RSV, and SARS-CoV-2. The kit also detects patients with any known variants, including Omicron, in a single process. Thus, such developments which utilize proteinase K enzymes in various molecular biology assays are anticipated to fuel the demand for proteinase K. Currently, as the pandemic has subsided, the market has lost some traction; however, it is expected to have stable growth during the forecast period of the study.

Factors such as the rising burden of chronic disorders and infectious diseases and the growing applications of diagnostic techniques and their associated enzymes for IVD are boosting market growth.

The growing burden of chronic and infectious diseases among the population is expected to increase market growth. For instance, according to the 2022 statistics published by IDF, about 537 million people were suffering from diabetes in 2021 globally, and this number is projected to reach 643 million and 784 million by 2030 and 2045, respectively. The rising disease burden is expected to increase the adoption of proteinase K, hence bolstering market growth.

Additionally, according to the British Heart Foundation England Factsheet, published in January 2022, about 6.4 million people were living with cardiovascular diseases in England in 2021. Also, according to the March 2022 update of the Australian Bureau of Statistics, the prevalence of heart disease in Australia was 4.0% in 2020-21, which equates to about 1 million people. Also, as per the same source, in Australia, heart disease increased with age, from 2.3% of people aged 45-54 years through to 23.2% of people aged 75 years and over, with males being the most affected by it in the country. Thus, the high burden of cardiovascular diseases among the population raises the demand for early diagnosis of the condition, which can be possible from proteinase K as it breaks down proteins, many of which have been implicated in various diseases, including cardiac disease. This is anticipated to fuel market growth.

Therefore, owing to the aforementioned factors, the studied market is expected to grow over the forecast period. However, the availability of new sophisticated technologies for DNA purification is likely to hamper the growth of the proteinase K market over the forecast period.

Proteinase K Market Trends

The Infectious Diseases Segment Expected to Register Significant Growth in the Market Over the Forecast Period

The infectious disease segment is expected to witness significant growth in the proteinase K market over the forecast period owing to the factors such as the rising burden of infectious diseases and the increasing wide applicability of proteinase K in the diagnosis of various infectious diseases.

The increasing incidences of infectious diseases such as pneumonia, hepatitis, COVID-19, and others are expected to increase the adoption of proteinase K in extracting RNA from the virus that helps in developing vaccines and drugs. This is anticipated to fuel the segment's growth. For instance, as per the data published by the WHO, in June 2022, about 1.5 million new cases of the hepatitis C virus were reported each year, with an estimated 58 million people worldwide having the infection, and as per the estimates, 3.2 million children and adolescents worldwide have chronic hepatitis C infection.

Also, as per the November 2022 update of the CDC, in the United States, about 11,269 patients were admitted to hospitals with influenza. As per the same source, in the current season, about 6.2 million cases and 53,000 hospitalizations were reported in the United States due to influenza. Similarly, as per the WHO Coronavirus (COVID-19) Dashboard, in the last week of November 2022, more than 2.9 million cases of new COVID-19 were reported globally, with the highest number of cases from the Western-Pacific region followed by Europe and the Americas.

Furthermore, various companies are offering proteinase K products that help in protein digestion during DNA and RNA extraction. Such an offering is expected to increase the availability of proteinase K products in the market, thereby boosting segment growth. For instance, QIAGEN offers QIAGEN Proteinase K and QIAGEN proteinase, broad substrate specificity with high activity, and is commonly used in most DNA and RNA isolation procedures for a wide range of reaction conditions.

Therefore, owing to the aforementioned factors, such as the high burden of infectious diseases and the rising availability of proteinase K products and kits, the studied segment is expected to grow over the forecast period.

North America Expected to Register Significant Growth in the Proteinase K Market Over the Forecast Period

North America is expected to witness significant growth in the proteinase K market over the forecast period. The factors attributing to the market growth are the increasing number of cancer and infectious diseases and growing next-generation sequencing and polymerase chain reaction applications. In addition, the presence of well-established healthcare infrastructure along with high healthcare expenditure as well as rising R&D expenditure in the region.

The rising prevalence of chronic diseases, such as cardiovascular diseases and cancer, and infectious diseases are the main factors driving the demand for proteinase K for extracting DNA and RNA, which is anticipated to fuel the market growth in the region over the forecast period. For instance, as per a research study published by Giuseppe Lippi et al. in July 2021, it was observed that about 6-12 million people in the United States are expected to suffer from atrial fibrillation by 2050 and 17.9 million people by 2060. Also, as per the statistics published by AHA, an estimated more than 130 million adults in the United States are expected to have some type of heart disease by 2035. As per WHO, as of December 2022, 71,69,653 confirmed cases of coronavirus were reported in Mexico.

Additionally, according to the Cancer Facts and Figures 2022 report by the American Cancer Society, an estimated 1.9 million new cancer cases were estimated to be diagnosed in the United States in 2022. Also, diabetes is one of the chronic illnesses which affects the population of all ages. For instance, as per the 2022 statistics published by IDF, about 2.9 million and 14.1 million people living in Canada and Mexico in 2021, and this number is projected to reach 3.4 million and 21.8 million, respectively, by 2045. Thus, the high burden of cancer and diabetes is anticipated to fuel the market growth over the forecast period.

Furthermore, the rising R&D spending in the region increases the company's focus on developing proteinase K kits and solutions, which in turn is anticipated to fuel the market growth in the region. For instance, as per the data published by the OECD, in August 2022, Canada spent USD 27,670 million on its R&D activities in 2021.

Therefore, due to the aforementioned factors, such as the rising burden of heart disease, diabetes, and cancer among the population and growing R&D activities, the studied market is expected to grow over the forecast period.

Proteinase K Industry Overview

The proteinase K market is moderately competitive, and few of the major players are currently dominating the market. Some of the key players in the market include Merck KGaA, F. Hoffmann-La Roche Ltd, Advanced Enzyme Technologies, Thermo Fisher Scientific, QIAGEN, G Biosciences, Dyadic International, Amicogen, and A and A Biotechnology.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Burden of Chronic and Infectious Diseases
  • 4.2.2 Growing Applications of Diagnostic Techniques and their Associated Enzymes for IVD
• 4.3 Market Restraints
  • 4.3.1 Availability of New Sophisticated Technologies for DNA Purification
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

• 5.1 By Form
  • 5.1.1 Powder
  • 5.1.2 Liquid
• 5.2 By Therapeutic Area
  • 5.2.1 Infectious Diseases
  • 5.2.2 Diabetes
  • 5.2.3 Oncology
  • 5.2.4 Cardiology
  • 5.2.5 Other Therapeutic Areas
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Merck KGaA
  • 6.1.2 F. Hoffmann-La Roche Ltd
  • 6.1.3 Advanced Enzymes Technologies
  • 6.1.4 Thermo Fisher Scientific
  • 6.1.5 Dyadic International
  • 6.1.6 QIAGEN
  • 6.1.7 Cell Signalling Technology Inc.
  • 6.1.8 Danaher Corporation (Leica Biosystems)
  • 6.1.9 G Bioscience
  • 6.1.10 Amicogen
  • 6.1.11 bioWORLD
  • 6.1.12 Promega Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS